Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
What is hemolytic disease of the newborn?
Hemolytic disease of the newborn (HDN) – also called erythroblastosis fetalis – is a blood disorder that occurs when the blood types of a mother and baby are incompatible. HDN is relatively uncommon in the United States due to advances in early detection and treatment, limiting it to approximately 4,000 cases a year. It is more likely to happen during a mother's second or subsequent pregnancy. There are two causes, Rh incompatibility and ABO incompatibility. HDN due to Rh incompatibility occurs more frequently and is often called Rh disease; it is about three times more likely in Caucasian babies than in African-American babies. HDN can be treated during pregnancy or after the baby is born.
How Dana-Farber/Boston Children's approaches hemolytic disease of the newborn
Hemolytic disease of the newborn (HDN) is treated through the Blood Disorders Center at Dana-Farber/Boston Children's. Hemolytic disease of the newborn was first identified in 1932 at Boston Children's Hospital by Dr. Louis Diamond. He went on to develop the first successful treatment, a transfusion procedure, in the 1940s.
Find in-depth information on hemolytic disease of the newborn on the Dana-Farber/Boston Children's website, including answers to:
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”